Overview

A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
A study to assess the safety, tolerability and efficacy of NVA237 versus placebo in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Bromides
Glycopyrrolate